Technical Analysis for URGN - UroGen Pharma Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 11.16 | 1.09% | 0.12 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 1.09% | |
| Lower Bollinger Band Walk | Weakness | 1.09% | |
| Below Lower BB | Weakness | 1.09% | |
| Down 3 Days in a Row | Weakness | 1.09% |
| Alert | Time |
|---|---|
| Possible NR7 | about 20 hours ago |
| Possible Inside Day | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Rose Above Lower Bollinger Band | about 23 hours ago |
| Up 1% | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 11/06/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Platform Technologies Bladder Cancer Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.7 |
| 52 Week Low | 10.6001 |
| Average Volume | 620,853 |
| 200-Day Moving Average | 14.62 |
| 50-Day Moving Average | 12.50 |
| 20-Day Moving Average | 12.07 |
| 10-Day Moving Average | 11.90 |
| Average True Range | 0.69 |
| RSI (14) | 36.71 |
| ADX | 20.37 |
| +DI | 19.05 |
| -DI | 22.68 |
| Chandelier Exit (Long, 3 ATRs) | 11.29 |
| Chandelier Exit (Short, 3 ATRs) | 12.70 |
| Upper Bollinger Bands | 13.00 |
| Lower Bollinger Band | 11.13 |
| Percent B (%b) | 0.02 |
| BandWidth | 15.52 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.22 |
| MACD Histogram | -0.1029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.72 | ||||
| Resistance 3 (R3) | 11.68 | 11.45 | 11.62 | ||
| Resistance 2 (R2) | 11.45 | 11.31 | 11.47 | 11.59 | |
| Resistance 1 (R1) | 11.31 | 11.22 | 11.38 | 11.35 | 11.56 |
| Pivot Point | 11.08 | 11.08 | 11.12 | 11.10 | 11.08 |
| Support 1 (S1) | 10.94 | 10.94 | 11.01 | 10.98 | 10.76 |
| Support 2 (S2) | 10.71 | 10.85 | 10.73 | 10.73 | |
| Support 3 (S3) | 10.57 | 10.71 | 10.70 | ||
| Support 4 (S4) | 10.61 |
